![Peter_Trill_Duke_St_Bio Dr Barry McGuinness Duke St Bio](https://dukestbio.com/wp-content/uploads/2021/09/Peter_Trill_Duke_St_Bio.jpg)
Peter Trill
Chairman, Co-Founder
As Chairman of Duke Street Bio, Peter draws on his extensive prior healthcare industry experience including advisory, investment and management roles.
He co-founded IOmet Pharma in 2008 where he was CFO, leading financing, business development and commercialisation strategies. Peter led the successful sale of IOmet to Merck/MSD in January 2016.
Before founding IOmet, Peter was a managing director and portfolio manager at Millennium Partners where he ran a global healthcare investment fund; he previously worked at both Morgan Stanley and UBS.
Management Team
Duke Street Bio has an experienced and proven management team with an exceptional track record of delivering clinical molecules across therapeutic areas.
![Alan_Wise_Duke_St_Bio Dr Alan Wise Duke St Bio](https://dukestbio.com/wp-content/uploads/2021/09/Alan_Wise_Duke_St_Bio.jpg)
Dr. Alan Wise
Chief Executive Officer
![Phil_Cowley_Duke_St_Bio Dr Phil Cowley Duke St Bio](https://dukestbio.com/wp-content/uploads/2021/09/Phil_Cowley_Duke_St_Bio.jpg)
Dr. Phill Cowley
Chief Scientific Officer
![Barry_McGuinness_Duke St_Bio Barry McGuinness](https://dukestbio.com/wp-content/uploads/2021/09/Barry_McGuinness_Duke-St_Bio.jpg)
Dr. Barry McGuinness
Chief Operating Officer
![](https://dukestbio.com/wp-content/uploads/2021/09/health-icon-10-2.png)
Delivering life-saving cancer treatments to improve patient outcomes.